Welcome to our dedicated page for Xtant Medical Holdings news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical Holdings stock.
Xtant Medical Holdings, Inc. reports developments as a medical technology company focused on surgical solutions for spinal and other orthopedic conditions. Its recurring updates include financial results, commercial activity in orthobiologics, and spinal implant systems used in complex spine, deformity, degenerative, wound care, and sports medicine applications.
Company news also covers product portfolio changes such as Trivium bone graft launches, U.S. distribution rights for HEMOBLAST Bellows, and completed divestitures involving Coflex, CoFix, and Paradigm Spine GmbH. These updates track how Xtant manages its biologics-focused portfolio, distribution channels, and surgical-product commercialization.
Xtant Medical (NYSE American: XTNT) will release fourth-quarter and full-year 2025 financial results before trading on Tuesday, March 31, 2026. A conference call with CEO Sean Browne and CFO Scott Neils is scheduled for 8:30 AM ET that day.
Investors can join by dial-in or webcast; a replay will be posted under "Investor info" on the company's website after the live call.
Xtant Medical (NYSE American: XTNT) announced completion of its Companion Spine divestitures after receiving $10.7 million on March 2, 2026, bringing the total aggregate purchase price to $21.4 million for the Coflex assets and Paradigm OUS businesses.
Of the $10.7 million, $8.2 million satisfied an unsecured promissory note (plus accrued interest) and $2.2 million related to working capital and purchase price adjustments. Management said the proceeds will help reduce long-term debt and provide additional cash liquidity while refocusing the company on higher-margin biologics.
Xtant Medical (NYSE: XTNT) said CEO Sean Browne, CFO Scott Neils, and COO Mark Schallenberger will participate in the Canaccord Genuity 2026 Musculoskeletal Conference on March 2, 2026, in New Orleans and virtually. A webcast will be available and management will offer virtual one-on-one meetings. A replay will be posted to Xtant's Presentation & Events page for 90 days.
Xtant Medical (NYSE American: XTNT) announced the commercial launch on December 11, 2025 of its next‑generation synthetic bone graft, nanOss Strata.
nanOss Strata is made from hydroxycarbonapatite (HCA), a more soluble material than traditional hydroxyapatite, and uses a nanocrystalline structure to more closely mimic human bone, increase surface area, improve osteoconductivity, and enhance cellular stimulation for integration and remodeling. Strata is offered as compression‑resistant preformed strips and prehydrated moldable grafts, both sterile, highly moldable, and designed to rapidly absorb blood and biologic fluids. The product is available through Xtant Medical's nationwide distribution network.
Companion Spine completed the acquisition of Paradigm Spine and its implants including Coflex® and CoFix® from Xtant Medical (NYSE:XTNT) on December 1, 2025. Paradigm Spine will retain its name and Wurmlingen, Germany office while joining Companion Spine's global portfolio.
Leadership roles were announced: Anthony G. Viscogliosi as Executive Chairman & CEO, Enrico Sangiorgio as EVP International and GM OUS, and William Pfost continuing as Chief Sales Officer focused on the U.S. The combined company now markets a broad set of posterior dynamic and motion-preserving implants, including multiple U.S. FDA PMA products.
Xtant Medical (NYSE: XTNT) completed the sale of certain non-core Coflex spinal implant assets and all OUS entities of Paradigm Spine to Companion Spine on Dec 1, 2025. The purchase price was approximately $19.2 million, consisting of $11.0 million cash and $8.2 million in short-term seller financing via an unsecured promissory note that is subject to purchase price adjustments and matures on Jan 15, 2026. Xtant intends to use net proceeds to reduce long-term debt and add liquidity, and said operating contributions of the sold assets are included through the Dec 1, 2025 sale date.
Xtant Medical (NYSE:XTNT) reported Q3 2025 revenue of $33.3M, up 19% YoY, with gross margin 66.1% versus 58.4% a year earlier. The company delivered net income $1.3M and adjusted EBITDA $4.5M, and generated $4.6M cash from operations. Cash and equivalents were $10.6M at 9/30/2025. Xtant reiterated full‑year 2025 revenue guidance of $131M–$135M (approx. 11%–15% growth over 2024).
Recent items: pending sale of certain hardware assets and all OUS businesses to Companion Spine expected to close by year‑end, and launch of CollagenX bovine collagen particulate for surgical wound closure. Webcast scheduled 11/11/2025 at 8:30 AM ET.
Xtant Medical (NYSE American: XTNT) announced the commercial launch of CollagenX™ on November 5, 2025. CollagenX is a bovine collagen particulate for surgical wound closure intended to promote healing, reduce dehiscence, and help mitigate concerns related to surgical site infections. The launch expands Xtant's biologics portfolio to address wound closure across spine, orthopedic, wound care, and other surgical disciplines. Management highlighted Xtant's vertical integration as a capability to deliver consistent quality for surgeons and patients.
Xtant Medical (NYSE American: XTNT) will release its third-quarter 2025 financial results for the period ended September 30, 2025 before market open on Tuesday, November 11, 2025. Sean Browne, President and CEO, and Scott Neils, Chief Financial Officer, will host a conference call at 8:30 AM ET the same day.
Conference dial-in details: 888-506-0062 (U.S.), international 973-528-0011, passcode 579614. A live webcast will be available at https://www.webcaster5.com/Webcast/Page/3039/52972, and a replay will be posted under Investor Info at https://xtantmedical.com/.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
CEO Sean Browne and CFO Scott Neils will represent the company at the conference, which takes place September 8-10, 2025, in New York and virtually. The company's presentation will be available on-demand starting September 5 at 7:00 A.M. ET. Management will also conduct virtual one-on-one meetings with investors on September 8th.